Research programme: cancer immunotherapeutics - Surface Oncology

Drug Profile

Research programme: cancer immunotherapeutics - Surface Oncology

Alternative Names: SRF 231

Latest Information Update: 10 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Surface Oncology
  • Class Antibodies; Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD47 antigen inhibitors; Immunomodulators; Nucleotidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Jun 2017 Surface Oncology in-licenses OmniRat®, OmniMouse® and OmniFlic® platforms technology from Ligand Pharmaceuticals
  • 08 Nov 2016 Surface Oncology plans clinical trial of SRF 231 for Cancer in 2017
  • 11 Jan 2016 Surface Oncology and Novartis agree to co-develop novel cancer immunotherapies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top